Secured £58M in an oversubscribed Series A round and received a £2 million grant from Innovate UK to advance its ion channel antibody development.
Founders
John McCafferty, Aneesh Karatt-Vellatt
Company Description
Maxion Therapeutics is a biotech company developing antibody-based KnotBody® drugs for ion channel and G protein-coupled receptor (GPCR) driven diseases, utilizing a proprietary platform that combines antibodies with cysteine-rich miniproteins to create potent and selective treatments.
Market
Biologic drug development for ion channel and GPCR-driven diseases
Location
Cambridge,
UK
Coinvestors
General Catalyst, British Patient Capital, Solasta Ventures, Eli Lilly and Company, LifeArc Ventures, Monograph Capital, BGF